Skip to main content
OUTCOME
4. Response capacity for communicable diseases
Communicable Diseases
4. Response capacity for communicable diseases
Budget
Approved Budget PB (Previous)
71.0
US$ MILLION
Priority

Medium

Proposed Budget PB (Current)
74.0
US$ MILLION
Related Outputs and Indicators
  • 4.1.a. Number of countries and territories implementing national norms, standards, and tools aligned with PAHO and WHO guidelines on TB, HIV, STIs, and VH, with emphasis on key and vulnerable populations
    Baseline
    12
    Target
    33
  • 4.2.a. Number of countries and territories implementing the new arboviral disease guidelines for patient care in the Region of the Americas
    Baseline
    11
    Target
    20
  • 4.3.a. Number of NID-endemic countries and territories that implement PAHO recommendations on integrated interventions to reduce the burden of NIDs through their health systems
    Baseline
    7
    Target
    19
  • 4.4.a. Number of countries and territories that implement PAHO/WHO-recommended policies and inter-programmatic approaches related to malaria
    Baseline
    10
    Target
    17
  • 4.5.a. Number of countries and territories with DPT3 immunization coverage of at least 95% that are implementing strategies to reach unvaccinated and under-vaccinated populations
    Baseline
    7
    Target
    27
  • 4.5.b. Number of countries and territories generating evidence to support decisions on the introduction or post-introduction of new vaccines
    Baseline
    14
    Target
    17
  • 4.6.a. Number of countries and territories that have conducted Integrated Management Strategy arbovirus evaluations
    Baseline
    2
    Target
    8
How PASB will deliver

Key Technical Cooperation Interventions
 

  • Step up leadership
    • Advocate and support the incorporation of innovative approaches to the prevention, detection, treatment, and care of HIV, STIs, viral hepatitis, TB, vector-borne diseases, and NIDs in line with WHO recommendations, including those introduced in response to the COVID-19 pandemic.

    • Promote intersectoral and multilevel approaches to improve equitable access to quality health care through prevention, surveillance, early detection, treatment, control, and care for HIV, STIs, viral hepatitis, TB, vector-borne diseases, NIDs, and vaccine-preventable diseases.

       

  • Support countries
    • Support countries in strengthening and modernizing immunization programs with renewed, high level political and social commitment, new tools for analysis to identify groups that are being left behind and the barriers that hinder their access, and innovative communication and social mobilization strategies to recover adequate vaccination coverage.
    • Enhance Member States’ capabilities to ensure equitable access to and distribution of COVID-19 vaccines, increasing access to boosters for vulnerable groups, identifying appropriate strategies to address vaccine hesitancy, and improving access to effective antivirals.
    • Provide technical cooperation to support Member States to develop strategies and plans focusing on a sustainable response to HIV, STIs, viral hepatitis, TB, vector-borne diseases, NIDs, and vaccine-preventable diseases, using person-centered and integrated approaches.
    • Improve country capacity for collection, analysis, and monitoring of data on HIV, STIs, viral hepatitis, TB, vector-borne diseases, NIDs, and vaccine-preventable diseases.

    • Support countries to develop study protocols and implement impact and effectiveness studies for new vaccines and operative research to support actions for the prevention, control, and elimination of communicable diseases.

       

  • Produce technical products on norms and standards, data, and research
    • Provide guidance and technical cooperation to strengthen the capacity of integrated health service networks toward the elimination of HIV, STIs, viral hepatitis, TB, vector-borne diseases, NIDs, and vaccine-preventable diseases, with a focus on the first level of care.